ATP-bioluminescence assay indicates the treatment of recurrent non-small cell lung cancer combined with malignant pleural effusion

Objective:This study was aimed to research the feasibility of ATP-bioluminescence assay(ATP-TCA) guiding the treatment on recurrent non-small cell lung cancer(NSCLC) combined with malignant pleural effusion.Methods:We collected 30 pleural fluid samples which were approved to be positive by cytology from recurrent NSCLC patients.These cells were cocultured with chemotherapy medicines,single agent or drugs combination.Five drug concentrations,two parallel holes were examined in vitro for 4 days,the results were measured by adding luciferase-fluorescein working system and luminescence analyzer.We applied chemotherapy medicines according to the results in vitro of ATP-TCA.Results:There were differences among drug sensitivities of individuals.All the samples could be evaluated.Effective single drugs included cisplatinum,mitomycin C,doxorubicin,and pemetrexed disodium;sensitive drugs in the combination therapy were gemcitabine plus cisplatin,vinorelbine plus cisplatin,paclitaxel plus cisplatin,docetaxel plus cisplatin,and mitomycin C,vindesine plus cisplatin,in which gemcitabine + cisplatin(GEM + DDP) in vitro was the most efficient program.Conclusion:ATP-TCA in vitro sensitivity assay is rapid,reliable,and simple to guide the treatment of recurrent NSCLC with malignant pleural effusion,and can help clinicians to make the individual chemotherapy program.

Report on the 10 cases of allergic reactions to oxaliplatin

Objective： The aim of this study was to investigate the mechanism, clinical manifestations, prevention and treatment measures of allergic reactions caused by oxaliplatin. Methods： Made detailed data about allergic reactions to oxaliplatin from 10 patients in our department, and made analysis and discussions about it while referring to related reference. Results： All the 10 patients had no history of allergies, 4 cases of allergies occurred during the course of multi-cycle chemotherapy, and 6 cases occurred on the first time of drug administration, whose allergic symptoms were present in the process of using oxaliplatin, with the infusion time from 10 to 25 rain. When relevant treatments such as drug withdrawal, hormone, intravenous calcium gluconate and magnesium sulfate were done to the patients, related symptoms could be soon relieved. Conclusion： Mechanisms of oxaliplatin allergic are still unclear. Applying calcium and magnesium may reduce the risk of neurotoxicity and reduce the degree of allergic reactions before administration of oxaliplatin.